(833) 317-6278 
Summary Background This study aimed to demonstrate the utility of the nasal Type I interferon (IFN-I) response as a marker for
The Lancet is a prestigious and influential medical journal that has been at the forefront of scientific publishing for nearly two centuries. Founded in 1823, this weekly general medical journal has a rich history of disseminating groundbreaking research and fostering important discussions that shape the field of medicine and healthcare.
As a leading voice in the scientific and healthcare community, The Lancet covers a wide range of topics related to health and wellbeing, healthcare, pharmaceuticals, and the broader societal impact of medical advancements. The journal is renowned for its rigorous peer-review process and its commitment to publishing high-quality, evidence-based research that can inform clinical practice, public health policies, and societal discourse.
The Lancet's readership includes medical professionals, researchers, policymakers, and individuals invested in the progress of healthcare and the betterment of human lives. The journal's content is highly regarded and frequently cited, shaping discussions and influencing decision-making processes in the medical field.
Through its scholarly articles, The Lancet presents cutting-edge research findings, expert commentary, and in-depth analyses, often drawing from diverse data sources, government announcements, legal policies, and regulatory frameworks. The journal also provides practical guidance and how-to resources to support the implementation of best practices in healthcare settings.
